Xentuzumab (BI 836845), an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive locally advanced/metastatic breast cancer: randomised Phase II results
John Crown, Marie-Paule Sablin, Javier Cortés, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, Peter Schmid
Learn more about the science behind this poster in the videos, papers and other materials below.
XENERA™-1: A Phase II trial of xentuzumab in combination with everolimus and exemestane in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer and non-visceral involvement
Peter Schmid, Hope S. Rugo, Javier Cortés, Dennis Chin-Lun Huang, Kate Crossley, Dan Massey, Howard A. Burris III
FOR HEALTHCARE PROFESSIONALS ONLY
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue